Jiangsu Hengrui Medicine Co., Ltd.

This early-phase study tests a new drug called HRS-4642 in people with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 102 adults with few other treatment op…

This study tests a new medication, SHR-3167, against a standard long-acting insulin (insulin degludec) in people with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and is safer. About 173 adults aged 18-65 with type 2 diab…

This phase 3 study tests whether a combination of two drugs (camrelizumab and famitinib) works better than standard chemotherapy for women with cervical cancer that has returned or spread. About 443 women who have not had prior treatment for advanced disease will be randomly assi…

This study tests an experimental drug called SHR0302Base in 155 adults with stable nonsegmental vitiligo, a condition causing white patches on the skin. The goal is to see if the drug can safely bring back skin color, especially on the face and neck. Participants take the drug or…

This phase 3 trial tests whether combining two drugs (camrelizumab and rivoceranib) can prevent liver cancer from returning in patients at high risk of recurrence after surgery or ablation. About 687 participants will receive either the drug combination or standard monitoring. Th…

This study tests a new drug called HRS-4642 combined with other anti-cancer medicines in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the combination is safe and helps shrink or control tumors. About 47 adults aged …

This study tests whether adding two drugs (camrelizumab and rivoceranib) to a standard liver cancer procedure (TACE) helps people with incurable liver cancer live longer without their disease getting worse. The trial includes 423 adults whose liver cancer cannot be removed by sur…

This study tests a new drug called SHR-A1811, given alone or with pertuzumab, against the standard treatment (trastuzumab, pertuzumab, and docetaxel) for women with HER2-positive breast cancer that has come back or spread. About 868 women aged 18 to 75 with measurable tumors and …

This study tests a new medicine called SHR-3167 in adults with type 2 diabetes whose blood sugar is not well controlled by pills. About 100 participants will receive different dosing plans to see which works best at lowering blood sugar while avoiding dangerously low sugar levels…

This early-phase study tests a new drug called HRS-6209 in 56 people with advanced solid tumors who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. This is a first step to see if the d…

This study tests whether adding a new drug (HR070803) to standard chemotherapy and targeted therapy can better control advanced colorectal cancer that has spread and cannot be removed by surgery. About 669 adults aged 18-75 who have not had prior treatment for their cancer will r…

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …

This study looks at how healthy men absorb, break down, and get rid of a single dose of a drug called HRS-9190. Six participants will provide blood, urine, and stool samples to measure the drug and its byproducts. The goal is to understand the drug's path in the body, not to trea…